Renata D'Alpino Peixoto1, Dante D Wan2, Devin Schellenberg2, Howard J Lim2. 1. British Columbia Cancer Agency, Vancouver, BC, Canada;; Hospital São José, São Paulo, Brazil;; Universidade Nove de Julho, São Paulo, Brazil. 2. British Columbia Cancer Agency, Vancouver, BC, Canada ;
Abstract
BACKGROUND: There are no randomized phase III trials comparing 5-fluorouracil/mitomycin (FM) versus capecitabine/mitomycin (CM) in combination with radiotherapy (RT) for locally advanced anal cancer. We aim to evaluate the outcomes of patients treated with FM and CM at our institution. METHODS: Patients with stage I-III anal cancer who initiated curative-intent RT (50-54 Gy) with either CM or FM between 1998 and 2013 at the BC Cancer Agency were reviewed. Cox proportional models were used to analyze the impact of regimen on disease-free survival (DFS) and anal cancer-specific survival (ACSS). RESULTS: A total of 300 patients were included. Baseline characteristics were well-distributed between the groups. A total of 194 patients (64.6%) received FM and 106 (35.3%) CM. The 2-year DFS was 79.7% for CM [95% confidence intervals (95% CI), 71.1-88.3%] and 78.8% for FM (95% CI, 73-84.6%); 2-year ACSS was 88.7% for CM (95% CI, 81.8-95.5%) and 87.5% for FM (95% CI, 82.8-92.2%). On multivariate analysis, only HIV status, clinical T size (≤5 vs. >5 cm), and N status (negative vs. positive) remained as significant prognostic factors for both DFS and ACSS. Chemotherapy regimen (CM vs. FM) had no impact on either DFS [P=0.995; hazard ratios (HR) =0.99; 95% CI, 0.57-1.74] or ACSS (P=0.847; HR =0.93; 95% CI, 0.46-1.86). CONCLUSIONS: In our population-based study, CM and FM concomitant with RT achieved similar DFS and ACSS. Substitution of capecitabine for infusional 5-FU may therefore be a reasonable option for patients and physicians who prefer to avoid the inconvenience and potential complications of a central infusional device.
BACKGROUND: There are no randomized phase III trials comparing 5-fluorouracil/mitomycin (FM) versus capecitabine/mitomycin (CM) in combination with radiotherapy (RT) for locally advanced anal cancer. We aim to evaluate the outcomes of patients treated with FM and CM at our institution. METHODS:Patients with stage I-III anal cancer who initiated curative-intent RT (50-54 Gy) with either CM or FM between 1998 and 2013 at the BC Cancer Agency were reviewed. Cox proportional models were used to analyze the impact of regimen on disease-free survival (DFS) and anal cancer-specific survival (ACSS). RESULTS: A total of 300 patients were included. Baseline characteristics were well-distributed between the groups. A total of 194 patients (64.6%) received FM and 106 (35.3%) CM. The 2-year DFS was 79.7% for CM [95% confidence intervals (95% CI), 71.1-88.3%] and 78.8% for FM (95% CI, 73-84.6%); 2-year ACSS was 88.7% for CM (95% CI, 81.8-95.5%) and 87.5% for FM (95% CI, 82.8-92.2%). On multivariate analysis, only HIV status, clinical T size (≤5 vs. >5 cm), and N status (negative vs. positive) remained as significant prognostic factors for both DFS and ACSS. Chemotherapy regimen (CM vs. FM) had no impact on either DFS [P=0.995; hazard ratios (HR) =0.99; 95% CI, 0.57-1.74] or ACSS (P=0.847; HR =0.93; 95% CI, 0.46-1.86). CONCLUSIONS: In our population-based study, CM and FM concomitant with RT achieved similar DFS and ACSS. Substitution of capecitabine for infusional 5-FU may therefore be a reasonable option for patients and physicians who prefer to avoid the inconvenience and potential complications of a central infusional device.
Authors: P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: J Cassidy; L Saltz; C Twelves; E Van Cutsem; P Hoff; Y Kang; J P Saini; F Gilberg; D Cunningham Journal: Ann Oncol Date: 2011-03-17 Impact factor: 32.976
Authors: E Touboul; M Schlienger; L Buffat; D Lefkopoulos; F Pène; R Parc; E Tiret; D Gallot; M Malafosse; A Laugier Journal: Cancer Date: 1994-03-15 Impact factor: 6.860
Authors: Rob Glynne-Jones; Helen Meadows; Susan Wan; Simon Gollins; Martin Leslie; Ed Levine; Alec C McDonald; Sun Myint; Les Samuel; David Sebag-Montefiore Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-09 Impact factor: 7.038
Authors: Frank G A Jansman; Maarten J Postma; David van Hartskamp; Pax H B Willemse; Jacobus R B J Brouwers Journal: Clin Ther Date: 2004-04 Impact factor: 3.393
Authors: Anna-Barbara Moscicki; Mark Schiffman; Ann Burchell; Ginesa Albero; Anna R Giuliano; Marc T Goodman; Susanne K Kjaer; Joel Palefsky Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: J Cassidy; J-Y Douillard; C Twelves; J J McKendrick; W Scheithauer; I Bustová; P G Johnston; K Lesniewski-Kmak; S Jelic; G Fountzilas; F Coxon; E Díaz-Rubio; T S Maughan; A Malzyner; O Bertetto; A Beham; A Figer; P Dufour; K K Patel; W Cowell; L P Garrison Journal: Br J Cancer Date: 2006-04-24 Impact factor: 7.640
Authors: Yoanna Pumpalova; Margaret M Kozak; Rie von Eyben; Pamela Kunz; George Fisher; Daniel T Chang; Sigurdis Haraldsdottir Journal: J Gastrointest Oncol Date: 2019-08
Authors: Robert Siegel; Ricardo Niklas Werner; Stephan Koswig; Matthew Gaskins; Claus Rödel; Felix Aigner Journal: Dtsch Arztebl Int Date: 2021-04-02 Impact factor: 8.251
Authors: Kathryn J Schunke; Lauren M Rosati; Marianna Zahurak; Joseph M Herman; Amol K Narang; Irina Usach; Alison P Klein; Charles J Yeo; Larry T Korman; Ralph H Hruban; John L Cameron; Daniel A Laheru; Ross A Abrams Journal: Adv Radiat Oncol Date: 2017-08-03